Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Arcutis Biotherapeutics Inc. (ARQT) PT Raised to $11 at Goldman Sachs, 'Zoryve launches trending positively'
February 28, 2024 3:31 AM ESTGoldman Sachs analyst Chris Shibutani raised the price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) to $11.00 (from $6.00) while maintaining a Neutral rating.
The analyst comments "ARQT reported 4Q23 results with net Zoryve (roflumilast cream) sales in plaque psoriasis of $13.5mn, above our and Visible Alpha Consensus estimates of... More
